Coxibs and cardiovascular side-effects: From lights to shadow

Current Pharmaceutical Design

Volumn 12, Issue 8, 2006, Pages 971-975

  Dogne, Jean Michel ^a   Hanson, Julien ^a   Supuran, Claudiu ^b   Pratico, Domenico ^c  

^a Laboratory of Medicinal Chemistry   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

COX 2 inhibitors; NSAIDs; Prostacyclin; Thrombosis; Valdecoxib

Indexed keywords

CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IV; CARBONATE DEHYDRATASE IX; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; ISOPROTEIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE A2; THROMBOXANE B2; UNINDEXED DRUG; VALDECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; COLORECTAL TUMOR; DECISION MAKING; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RISK ASSESSMENT; STOMACH EPITHELIUM; STOMACH ULCER; STROKE; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; TISSUE DISTRIBUTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; EPOPROSTENOL; HUMANS; ISOXAZOLES; LACTONES; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES; THROMBOXANE A2;

EID: 33646010355     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055949     Document Type: Review

References (20)

1. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-90.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
4. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9.
5. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 2004; 11: 1243-52.
6. Dogne JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004; 11: 1223-41.
7. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
8. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
9. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-66.
10. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003; 63: 33-45.
11. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-32.
12. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
13. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
14. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004; 177: 235-43.
15. Supuran CT, Casini A, Mastrolorenzo A, Scozzafava A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem 2004; 4: 625-32.
16. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004; 47: 550-7.
17. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004; 33: 1-6.
18. Claria J. Cyclooxygenase-2 biology. Curr Pharm Design 2003; 9(27): 2177-90.
19. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Design 2004; 10(6): 577-88.
20. Skelly MM, Hawkey CJ. Dual COX inhibition and upper gastrointestinal damage. Curr Pharm Design 2003; 9(27): 2191-5.